MGL 3196

Drug Profile

MGL 3196

Alternative Names: MGL3196; VIA-3196

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Madrigal Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Nitriles; Pyridazines; Small molecules; Triazines
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Feb 2018 Efficacy and adverse events data from a phase II trial in Hyperlipoproteinaemia type IIa released by Madrigal
  • 29 Jan 2018 Madrigal Pharmaceuticals plans a phase I trial in healthy volunteers in the US in February 2018 (NCT03413124)
  • 15 Jan 2018 Madrigal Pharmaceuticals completes a phase II trial in Hyperlipoproteinaemia type IIa (Adjunctive treatment) in Denmark (PO) (NCT03038022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top